Prescreening Study to Identify Potential Wilson Disease Participants for Gene-Editing Clinical Trial
← catalyst calendarNCT07226622 · readout ≤ 499 d
Sponsored by Prime Medicine, Inc. (industry) · PRME — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
30estimated
Sites
7
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-29 | actual | When the study began enrolling |
| Primary completion | Dec 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2025-11-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Wilson Disease
Primary outcome
what the primary-completion date above is the date OFGene Editing Interest & Attitudes Survey
measured From enrollment to the end of study 90 days
Permalink · PRME's whole pipeline · Catalyst calendar · Every registered study · What changed